NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $81.69 -1.51 (-1.81%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About GeneDx Stock (NASDAQ:WGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeneDx alerts:Sign Up Key Stats Today's Range$77.69▼$83.3050-Day Range$29.62▼$84.0252-Week Range$1.16▼$89.11Volume781,807 shsAverage Volume438,132 shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/APrice Target$59.33Consensus RatingModerate Buy Company OverviewGeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.Read More… $5k to $1.3m in just 3 trades (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. GeneDx Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks24th Percentile Overall ScoreWGS MarketRank™: GeneDx scored higher than 24% of companies evaluated by MarketBeat, and ranked 906th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($0.75) to $0.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -18.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -18.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 9.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.55% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in GeneDx has recently increased by 8.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.55% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in GeneDx has recently increased by 8.60%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.44 News SentimentGeneDx has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for GeneDx this week, compared to 3 articles on an average week.Search Interest26 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 189% compared to the previous 30 days.MarketBeat Follows7 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,770,553.00 in company stock.Percentage Held by Insiders27.30% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Email Address WGS Stock News HeadlinesGeneDx Holdings Corp. (NASDAQ:WGS) Q3 2024 Earnings Call TranscriptOctober 31 at 9:45 AM | msn.comGeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium TermOctober 30 at 3:10 PM | seekingalpha.com$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.October 31, 2024 | Insiders Exposed (Ad)GeneDx price target raised to $95 from $70 at Craig-HallumOctober 30 at 1:36 PM | markets.businessinsider.comGeneDx price target raised to $95 from $45 at BTIGOctober 30 at 4:17 AM | markets.businessinsider.comGeneDx Holdings Corp (WGS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and First ...October 30 at 3:33 AM | finance.yahoo.comGeneDx price target raised to $75 from $34 at Wells FargoOctober 29 at 11:15 PM | markets.businessinsider.comGeneDx Holdings: Impressive Growth Undermined by High Valuation Leading to Hold RatingOctober 29 at 11:15 PM | markets.businessinsider.comSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $2.75 at the start of the year. Since then, WGS shares have increased by 2,870.5% and is now trading at $81.69. View the best growth stocks for 2024 here. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) posted its earnings results on Monday, November, 15th. The company reported $4.95 earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.27) by $11.22. The firm had revenue of $43.18 million for the quarter, compared to analysts' expectations of $42 million. GeneDx had a negative net margin of 48.21% and a negative trailing twelve-month return on equity of 22.71%. When did GeneDx's stock split? GeneDx's stock reverse split on the morning of Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? Top institutional investors of GeneDx include Assenagon Asset Management S.A. (1.26%), Raymond James & Associates (0.73%), Principal Financial Group Inc. (0.05%) and Precision Wealth Strategies LLC (0.03%). Insiders that own company stock include Casdin Capital, Llc, Opko Health, Inc, Tactical Opportunit Blackstone, Jason Ryan, Kevin Feeley, Kareem Saad, Richard C Pfenniger Jr, Daniel Emmett Clark, Isaac Ro, Eric Schadt, Karen Ann White, Shawn Assad, Richard Miao and Anthony Prentice. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings11/15/2021Today10/31/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryHealthcare Current SymbolNASDAQ:WGS CUSIPN/A CIK1818331 Websema4.com Phone800-298-6470FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$59.33 High Stock Price Target$95.00 Low Stock Price Target$21.00 Potential Upside/Downside-28.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-175,770,000.00 Net Margins-48.21% Pretax Margin-48.56% Return on Equity-22.71% Return on Assets-12.39% Debt Debt-to-Equity Ratio0.27 Current Ratio2.38 Quick Ratio2.22 Sales & Book Value Annual Sales$267.23 million Price / Sales8.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.78 per share Price / Book9.44Miscellaneous Outstanding Shares26,936,000Free Float19,582,000Market Cap$2.23 billion OptionableOptionable Beta2.32 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:WGS) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.